Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone plus Insulin in Type 2 Diabetes
NCT00349427Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Rosiglitazone + Insulin with Placebo + Insulin (2 arms). Primary endpoint: Glycosylated hemoglobin at 24 weeks. Started Oct 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00349427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349427.